Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
221 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | recruiting | Phase 3 | 1,314 | Merck Sharp & Dohme LLCINDUSTRY | 39 | Sep 25, 2026 | clinicaltrials |
| NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | recruiting | Phase 3 | 900 | PfizerINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
| NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 736 | BioNTech SEINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer(rechARge) | active not recruiting | Phase 3 | 960 | CelgeneINDUSTRY | 23 | Sep 8, 2026 | clinicaltrials |
| NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)(Himalayas-1) | recruiting | Phase 3 | 600 | ORIC PharmaceuticalsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | recruiting | Phase 3 | 1,524 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05171816 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | active not recruiting | Phase 3 | 110 | AstraZenecaINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT03732820 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 17 | Aug 18, 2026 | clinicaltrials |
| NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | recruiting | Phase 3 | 520 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 6 | Jul 21, 2026 | clinicaltrials |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | active not recruiting | Phase 3 | 707 | AmgenINDUSTRY | 22 | May 15, 2026 | clinicaltrials |
| NCT06439225 | Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes(OPTION-DDR) | recruiting | Phase 3 | 236 | Canadian Cancer Trials GroupNETWORK | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02044354 | Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer(CABA-DOC) | completed | Phase 3 | 195 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy(CASPAR) | active not recruiting | Phase 3 | 61 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment(SPLASH) | active not recruiting | Phase 3 | 455 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 6 | Jan 13, 2026 | clinicaltrials |
| NCT02975934 | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON3) | completed | Phase 3 | 405 | pharmaand GmbHINDUSTRY | 12 | Jul 25, 2025 | clinicaltrials |
| NCT05547386 | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 163 | Mayo ClinicOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone(PRESIDE) | completed | Phase 3 | 688 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT06768255 | Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC(mCRPC) | not yet recruiting | Phase 3 | 400 | Ding-Wei YeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer(MEDCARE) | recruiting | Phase 3 | 246 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 3 | 104 | Hinova Pharmaceuticals USA, Inc.INDUSTRY | 14 | Aug 19, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent(VERACITY) | terminated | Phase 3 | 105 | Veru Inc.INDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04887506 | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | completed | Phase 3 | 107 | Tavanta TherapeuticsINDUSTRY | 8 | Jan 16, 2024 | clinicaltrials |
| NCT02987543 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | completed | Phase 3 | 387 | AstraZenecaINDUSTRY | 20 | Oct 6, 2023 | clinicaltrials |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients(ESCALATE) | terminated | Phase 3 | 23 | MANA RBMOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT01517802 | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | completed | Phase 3 | 32 | Janssen Research & Development, LLCINDUSTRY | 7 | May 10, 2022 | clinicaltrials |
| NCT02111577 | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer(VIABLE) | completed | Phase 3 | 1,182 | SOTIO a.s.INDUSTRY | 22 | Apr 6, 2021 | clinicaltrials |
| NCT04056754 | Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer | completed | Phase 3 | 268 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2019 | clinicaltrials |
| NCT00974311 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy(AFFIRM) | completed | Phase 3 | 1,199 | PfizerINDUSTRY | 15 | Dec 11, 2018 | clinicaltrials |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer(COMET-2) | terminated | Phase 3 | 119 | ExelixisINDUSTRY | 5 | May 23, 2018 | clinicaltrials |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100(COMET-1) | completed | Phase 3 | 1,028 | ExelixisINDUSTRY | 14 | Mar 14, 2018 | clinicaltrials |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | terminated | Phase 2 / Phase 3 | 12 | University Hospital, GrenobleOTHER | 1 | Apr 28, 2016 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials